Recently I posted a reply about a pembrolizumab (Keytruda) Trial that showed only a small 3-6% of patients had a "response", and then noted OS was less than 10 months. It occurs to me that my attitude in that post was stupid and un-generous. For that I now apologize.
All participants in cancer clinical trials are heroes. They are putting their lives literally on the line to advance the knowledge that will hopefully add some measure of knowledge to this very complicated fight that we share. And yes there is the hope that the trial will provide a personal benefit in their own fight. Yet, those who participate in controlled randomized trials know that they may not even receive the study treatment. This is especially humbling to consider in trials where the holy grail of results is being evaluated: OS or Overall Survival advantage of significance.
Every data point in an OS statistic is a life. And a death. They are all-in, these heroes. PSA responses and PFE, Progression Free Survival and its permutations are fine. But we do not truly know a treatment is effective until we have that most important measure of prolonged survival. And that requires participants who are willing to go all-in. And this does not apply only to the trials that show a positive impact on OS. It applies equally to trials that result in no measurable advantages over SOC or comparing any other two arms. For the negative results showing that a particular intervention does not extend survival is just as important. All of these takes our knowledge and our tools and our weapons in this fight further. It serves all of us now and those who will come after.
I shall never again read a research article or abstract that reports on OS without pausing for a moment to honor those brave heroes, our brothers and sisters in arms in the fight against cancer. OS research heroes I honor and bow to you.